<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04657562</url>
  </required_header>
  <id_info>
    <org_study_id>2019/33/N/NZ7/01631</org_study_id>
    <nct_id>NCT04657562</nct_id>
  </id_info>
  <brief_title>The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma</brief_title>
  <acronym>FreeTAC</acronym>
  <official_title>Development and Validation of New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma in CYP3A5 Expressors and Non-Expressors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Science Centre, Poland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Science Centre, Poland</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tacrolimus (TAC) is characterized by a narrow therapeutic window, as well as high inter- and&#xD;
      intra-individual variability in pharmacokinetics. Both under- and overexposure may lead to&#xD;
      severe adverse effects. Therapeutic drug monitoring (TDM) is an essential element of&#xD;
      post-transplant patient care. Most transplantation centers use C0 to adjust TAC dosage. Some&#xD;
      controversies remain about relationship between C0 and clinical outcome.&#xD;
&#xD;
      It is generally accepted that only protein-unbound drug molecules can cross cellular&#xD;
      membranes, which imply that TDM of free tacrolimus fraction may be of paramount importance&#xD;
      and improve clinical management of organ recipients.&#xD;
&#xD;
      Whole blood TAC concentrations and dose requirements are strongly associated with CYP3A5&#xD;
      polymorphism. Routine CYP3A5 genotyping on the waiting lists might be useful to guide&#xD;
      tacrolimus dosing.&#xD;
&#xD;
      This interdisciplinary project tackles the research problem from three angles - biochemistry,&#xD;
      genetics and clinical observation. The primary goal of the study is to evaluate clinical&#xD;
      usefulness of different TDM protocols in patients after kidney and liver transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As there are over 15.000 patients in Poland on continuous tacrolimus (TAC) therapy, the&#xD;
      identification and validation of more sensitive and specific biomarkers is of utmost&#xD;
      importance. The investigators propose a multiple step assessment of TAC therapeutic drug&#xD;
      monitoring (TDM) in kidney and liver recipients. A role of genetic profiling on drug&#xD;
      concentration and clinical effects will also be addressed. The project will significantly&#xD;
      contribute to understanding tacrolimus pharmacokinetics and body response to drug exposure.&#xD;
      Moreover, the proposed project is the first attempt to integrate both different TDM measure&#xD;
      methods and patient genetics in a rigorous, prospective study with the assessment of the&#xD;
      clinical over- and underexposure TAC effects. It is expected to provide an argument for&#xD;
      implementation of even more personalized, predictable immunosuppressive therapy.&#xD;
&#xD;
      The investigators hypothesize that:&#xD;
&#xD;
        1. There is a correlation of free TAC level with drug toxicity on one hand, and graft&#xD;
           rejection and underimmunosuppression despite target whole blood concentration on the&#xD;
           other.&#xD;
&#xD;
        2. CYP3A5 expressors and non-expressors will present different levels of TAC in both whole&#xD;
           blood C0 and free TAC C0 as well as different effectiveness and toxicity profiles.&#xD;
&#xD;
        3. The concentration of free TAC is related to changes in the concentration of blood&#xD;
           components, thus it is possible to derive the equation for calculating free TAC fraction&#xD;
           as a useful tool for the drug dosage adjustment.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The group: 110 consecutive adult kidney or liver transplant on TAC-based immunosuppression,&#xD;
      who declare to attend the local outpatient clinic for at least one year. Another exclusion&#xD;
      criteria are HBV, HCV and HIV infection, neurological disordesr, intake of drugs affecting&#xD;
      TAC metabolism.&#xD;
&#xD;
      Objectives: A primary objective of this study is to look for a correlation between unbound&#xD;
      TAC level in an ultrafiltrate with symptoms of drug toxicity, and graft rejection episodes.&#xD;
      Also, a complex comparison of different methods of determination of TAC concentration in&#xD;
      whole blood, plasma and ultrafiltrate is planned. Secondary aim of the study is to calculate&#xD;
      free fraction of TAC from hematocrit level, albumin concentration and routine whole blood TAC&#xD;
      C0 to predict dose adjustment more accurately. The generated equation will be plot against&#xD;
      CYP3A polymorphisms. The benefit of genotyping before administration of TAC for dose&#xD;
      prediction will be evaluated.&#xD;
&#xD;
      Database and endpoints: a Case Report Form (CRF) was designed. Primary endpoints are:&#xD;
      treatment failure, 12-month overall patient and graft survival. Secondary end points are side&#xD;
      effects of tacrolimus toxicity: kidney graft function, liver graft function, new-onset&#xD;
      diabetes mellitus after transplantation or worsening of former diabetes control, new arterial&#xD;
      hypertension or worsening of former hypertension control, metabolic disorders (dyslipidemia,&#xD;
      hypomagesemia, hypokalemia), neurotoxicity (especially post-transplant tremors), digestive&#xD;
      disorders, cardiovascular events, infections and neoplasms' occurrence.&#xD;
&#xD;
      TAC measure: free TAC in ultrafiltrate, plasma and whole blood C0 will be measured (day: 3,&#xD;
      5, 7, 14, 360).&#xD;
&#xD;
      Genotyping: CYP3A4 and CYP3A5 polymorphisms will be recorded. Study duration: The study is&#xD;
      scheduled for 3 years: 1-1.5 years for collection of samples, 1 year of follow-up after&#xD;
      transplantation, 0.5 year for analysis and publication of the results.&#xD;
&#xD;
      Efficacy variables: Standard monitoring of blood and urine laboratory parameters in de novo&#xD;
      renal or liver transplant recipients during first year after transplantation, neurological&#xD;
      examination including The Essential Tremor Rating Assessment Scale (TETRAS), whole blood TAC&#xD;
      trough level (C0), plasma TAC concentration, free TAC concentration in plasma ultrafiltrate,&#xD;
      TAC daily dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>A comparison of different TAC TDM protocols depending on the matrix</measure>
    <time_frame>1 year</time_frame>
    <description>concentration of unbound tacrolimus in plasma ultrafiltrate&#xD;
concentration of tacrolimus in plasma&#xD;
concentration of tacrolimus in whole blood The measures will be obtained with the use of LC-MS/MS method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>In liver and kindey recipients 2. concentration of tacrolimus in plasma 3. concentration of tacrolimus in whole blood The measures will be obtained with the use of LC-MS/MS method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loss of graft function</measure>
    <time_frame>1 year</time_frame>
    <description>In liver and kindey recipients 2. concentration of tacrolimus in plasma 3. concentration of tacrolimus in whole blood The measures will be obtained with the use of LC-MS/MS method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal graft function</measure>
    <time_frame>1 year</time_frame>
    <description>Delayed graft function defined as failure of the renal transplant to function immediately, with the need for dialysis in the first post-transplantation week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal graft function</measure>
    <time_frame>1 year</time_frame>
    <description>Estimated glomerular filtration rate calculated by the abbreviated MDRD equation : 186 x (Creatinine/88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver graft function</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment with the use of MELD-Na score and Child-Pugh score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and nephrotoxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Acute Kidney Injury episodes (KDIGO definition)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and nephrotoxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Calcineurin inhibitor toxicity confirmed with the biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and neurotoxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Occurrence of headaches, tremors, blurred vision, seizures, focal symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and tremors</measure>
    <time_frame>1 year</time_frame>
    <description>Assessed with the use of The Essential Tremor Rating Assessment Scale (TETRAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and new diabetes mellitus</measure>
    <time_frame>1 year</time_frame>
    <description>New-onset diabetes mellitus after transplantation&#xD;
Worsening of former diabetes control Based on pre- and posttransplant glucose measures (mg% and mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and new artrial hypertension</measure>
    <time_frame>1 year</time_frame>
    <description>New AH&#xD;
Worsening of former AH control Based on pre- and postoperative blood preassure measures (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and new metabolic disorders</measure>
    <time_frame>1 year</time_frame>
    <description>hyperlipidemia, hyperuricemia, hyperkalemia, hypomagnesemia - based on biochemical measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>Based on clinical observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and gastrointestinal side effects</measure>
    <time_frame>1 year</time_frame>
    <description>Based on clinical observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and infections</measure>
    <time_frame>1 year</time_frame>
    <description>Based on clinical observation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and new neoplasms</measure>
    <time_frame>1 year</time_frame>
    <description>Based on a histopathological examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A correlation between free TAC and symptoms of underimmunosuppresion</measure>
    <time_frame>1 year</time_frame>
    <description>Biopsy proven acute rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYP3A expression</measure>
    <time_frame>1 year</time_frame>
    <description>SNP genotyping to address CYP3A genetic variations (CYP3A4 and CYP3A5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood components</measure>
    <time_frame>1 year</time_frame>
    <description>Hematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood components</measure>
    <time_frame>1 year</time_frame>
    <description>Plasma albumins and proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood components</measure>
    <time_frame>1 year</time_frame>
    <description>Total, LDL and HDL cholesterol, triglycerid</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Immunosuppression</condition>
  <condition>Kidney Transplant Rejection</condition>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Liver Transplant Rejection</condition>
  <condition>Liver Transplant; Complications</condition>
  <condition>Metabolism Medication Toxicity</condition>
  <condition>Genetic Predisposition</condition>
  <arm_group>
    <arm_group_label>Kidney/Liver transplant recipients</arm_group_label>
    <description>The group will consist of 110 adult (age &gt; 18 years) male and female recipients of deceased kidney or liver transplant from the Regional Qualification Center (Warsaw, Poland).&#xD;
Additional 10% of patients will be included to the study to compensate for follow-up loss or blood samples destabilization (total N=121).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Prevention of rejection in kidney or liver transplant: a standard immunosuppressive therapy according to international protocols.</description>
    <arm_group_label>Kidney/Liver transplant recipients</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (2 ml and 10 ml test-tubes with EDTA) will be collected on 3rd-4th, 5th-6th,&#xD;
      7th-8th, 14th day and 1 year after transplantation procedure.&#xD;
&#xD;
        1. The plasma ultrafiltrate will be obtained to measure unbound tacrolimus concentration&#xD;
&#xD;
        2. The plasma will be obtained to measure plasma tacrolimus concentration&#xD;
&#xD;
        3. The whole blood will be obtained to measure tacrolimus through concentration&#xD;
&#xD;
        4. The DNA will be purified from whole blood and analyzed (RT-PCR).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The group will consist of 110 adult (age &gt; 18 years) recipients of kidney or liver&#xD;
        transplant from the Regional Qualification Center. Patients requiring perioperatively&#xD;
        agents significantly influencing TAC metabolism will be excluded from the study, as well as&#xD;
        nonadherent patients and double organ recipients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult (&gt;18 yo), recipient of kidney or liver transplant from the Regional&#xD;
             Qualification Center, tacrolimus-based immunosuppression&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the use of agents significantly influencing TAC metabolism, double organ recipients,&#xD;
             HBV, HCV and HIV infection, neurological disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karola Warzyszyńska, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of General and Transplant Surgery, Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karola Warzyszyńska, MD</last_name>
    <phone>+48225021783</phone>
    <email>karola.warzyszynska@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of General and Transplant Surgery, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-006</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karola Warszyszynska, MD</last_name>
      <phone>225021784</phone>
      <phone_ext>+48</phone_ext>
      <email>karola.warzyszynska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Karola Warzyszynska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.</citation>
    <PMID>19845597</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016 Feb;64(2):433-485. doi: 10.1016/j.jhep.2015.10.006. Epub 2015 Nov 17.</citation>
    <PMID>26597456</PMID>
  </reference>
  <reference>
    <citation>Bittersohl H, Schniedewind B, Christians U, Luppa PB. A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. J Chromatogr A. 2018 Apr 27;1547:45-52. doi: 10.1016/j.chroma.2018.03.010. Epub 2018 Mar 7.</citation>
    <PMID>29544893</PMID>
  </reference>
  <reference>
    <citation>Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. Review.</citation>
    <PMID>31045868</PMID>
  </reference>
  <reference>
    <citation>Ekberg H, Tedesco-Silva H, Demirbas A, Vítko S, Nashan B, Gürkan A, Margreiter R, Hugo C, Grinyó JM, Frei U, Vanrenterghem Y, Daloze P, Halloran PF; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 Dec 20;357(25):2562-75.</citation>
    <PMID>18094377</PMID>
  </reference>
  <reference>
    <citation>Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F; TRANSFORM Investigators. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. J Am Soc Nephrol. 2018 Jul;29(7):1979-1991. doi: 10.1681/ASN.2018010009. Epub 2018 May 11.</citation>
    <PMID>29752413</PMID>
  </reference>
  <reference>
    <citation>Stienstra NA, Sikma MA, van Dapperen AL, de Lange DW, van Maarseveen EM. Development of a Simple and Rapid Method to Measure the Free Fraction of Tacrolimus in Plasma Using Ultrafiltration and LC-MS/MS. Ther Drug Monit. 2016 Dec;38(6):722-727.</citation>
    <PMID>27805928</PMID>
  </reference>
  <reference>
    <citation>Bouamar R, Shuker N, Hesselink DA, Weimar W, Ekberg H, Kaplan B, Bernasconi C, van Gelder T. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials(†). Am J Transplant. 2013 May;13(5):1253-61. doi: 10.1111/ajt.12191. Epub 2013 Mar 8.</citation>
    <PMID>23480233</PMID>
  </reference>
  <reference>
    <citation>Israni AK, Riad SM, Leduc R, Oetting WS, Guan W, Schladt D, Matas AJ, Jacobson PA; DeKAF Genomics Investigators. Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics. Transpl Int. 2013 Oct;26(10):982-9. doi: 10.1111/tri.12155. Epub 2013 Jul 24.</citation>
    <PMID>23879408</PMID>
  </reference>
  <reference>
    <citation>Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation. 1996 Oct 15;62(7):920-6.</citation>
    <PMID>8878385</PMID>
  </reference>
  <reference>
    <citation>Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit. 2004 Oct;26(5):506-15.</citation>
    <PMID>15385833</PMID>
  </reference>
  <reference>
    <citation>Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001 Jul-Aug;46(1):27-35.</citation>
    <PMID>12164257</PMID>
  </reference>
  <reference>
    <citation>Hendijani F, Azarpira N, Kaviani M. Effect of CYP3A5*1 expression on tacrolimus required dose for transplant pediatrics: A systematic review and meta-analysis. Pediatr Transplant. 2018 Jun 19:e13248. doi: 10.1111/petr.13248. [Epub ahead of print] Review.</citation>
    <PMID>29920880</PMID>
  </reference>
  <reference>
    <citation>Rojas L, Neumann I, Herrero MJ, Bosó V, Reig J, Poveda JL, Megías J, Bea S, Aliño SF. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015 Feb;15(1):38-48. doi: 10.1038/tpj.2014.38. Epub 2014 Sep 9. Review.</citation>
    <PMID>25201288</PMID>
  </reference>
  <reference>
    <citation>Haufroid V, Wallemacq P, VanKerckhove V, Elens L, De Meyer M, Eddour DC, Malaise J, Lison D, Mourad M. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006 Nov;6(11):2706-13.</citation>
    <PMID>17049058</PMID>
  </reference>
  <reference>
    <citation>Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995 Dec;29(6):404-30. Review.</citation>
    <PMID>8787947</PMID>
  </reference>
  <reference>
    <citation>Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther. 2004 May;75(5):434-47.</citation>
    <PMID>15116056</PMID>
  </reference>
  <reference>
    <citation>Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, Kohnle M, Zanker B, Land W, Morales JM, Andrés A, Schäfer A, Stevenson P. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999 Feb-Mar;31(1-2):296-8.</citation>
    <PMID>10083114</PMID>
  </reference>
  <reference>
    <citation>Zong YP, Wang ZJ, Zhou WL, Zhou WM, Ma TL, Huang ZK, Zhao CC, Xu Z, Tan RY, Gu M. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies. World J Pediatr. 2017 Oct;13(5):421-426. doi: 10.1007/s12519-017-0035-4. Epub 2017 May 24. Review.</citation>
    <PMID>28540692</PMID>
  </reference>
  <reference>
    <citation>Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010 Oct 7;363(15):1451-62. doi: 10.1056/NEJMra0902927. Review.</citation>
    <PMID>20925547</PMID>
  </reference>
  <reference>
    <citation>Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994 Aug 13;344(8920):423-8.</citation>
    <PMID>7520105</PMID>
  </reference>
  <reference>
    <citation>U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994 Oct 27;331(17):1110-5.</citation>
    <PMID>7523946</PMID>
  </reference>
  <reference>
    <citation>de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis. 2000 Feb;35(2):333-46. Review.</citation>
    <PMID>10676738</PMID>
  </reference>
  <reference>
    <citation>Elble R, Comella C, Fahn S, Hallett M, Jankovic J, Juncos JL, Lewitt P, Lyons K, Ondo W, Pahwa R, Sethi K, Stover N, Tarsy D, Testa C, Tintner R, Watts R, Zesiewicz T. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct;27(12):1567-9. doi: 10.1002/mds.25162. Epub 2012 Oct 2.</citation>
    <PMID>23032792</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>December 1, 2020</last_update_submitted>
  <last_update_submitted_qc>December 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Science Centre, Poland</investigator_affiliation>
    <investigator_full_name>Karola Warzyszyńska</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Kidney transplant</keyword>
  <keyword>liver transplant</keyword>
  <keyword>CYP3A</keyword>
  <keyword>unbound tacrolimus</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication will be available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After publication of the study results (about 2022).</ipd_time_frame>
    <ipd_access_criteria>Non-comercial, after request</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

